We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+37.1%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$622M
AUM Growth
+$195M
Cap. Flow
+$80.5M
Cap. Flow %
12.95%
Top 10 Hldgs %
55.49%
Holding
44
New
12
Increased
14
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$20.9M
2
STRO icon
Sutro Biopharma
STRO
+$18.1M
3
NTRA icon
Natera
NTRA
+$13M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$11.6M
5
ETNB
89bio
ETNB
+$10.7M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$16.9M
2
CBAY
Cymabay Therapeutics
CBAY
+$14.4M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$12.7M
4
GPCR icon
Structure Therapeutics
GPCR
+$9.4M
5
VKTX icon
Viking Therapeutics
VKTX
+$7.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$130M 20.95%
7,648,268
– –
GERN icon
2
Geron
GERN
$970M
$34.6M 5.56%
10,475,675
-239,945
-2% -$538K
IOVA icon
3
Iovance Biotherapeutics
IOVA
$3.63B
$32.6M 5.24%
2,200,000
-1,089,470
-33% -$12.7M
ZNTL icon
4
Zentalis Pharmaceuticals
ZNTL
$360M
$23.9M 3.84%
+1,516,183
New +$20.9M
ITOS
5
DELISTED
iTeos Therapeutics
ITOS
$23.8M 3.83%
1,745,943
– –
STRO icon
6
Sutro Biopharma
STRO
$339M
$23.1M 3.72%
+409,662
New +$18.1M
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$9B
$22.5M 3.62%
480,588
+2,354
+0.5% +$92.1K
OLMA icon
8
Olema Pharmaceuticals
OLMA
$899M
$22.1M 3.56%
1,953,690
+96,554
+5% +$1.25M
MDGL icon
9
Madrigal Pharmaceuticals
MDGL
$12.3B
$16.4M 2.64%
61,399
+20,489
+50% +$4.83M
NTRA icon
10
Natera
NTRA
$47B
$15.8M 2.54%
+172,413
New +$13M
HOWL icon
11
Werewolf Therapeutics
HOWL
$45.8M
$15.5M 2.49%
2,388,011
– –
MLTX icon
12
MoonLake Immunotherapeutics
MLTX
$1.28B
$14.9M 2.39%
296,050
+1,474
+0.5% +$80K
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$14.7M 2.37%
871,149
+206,163
+31% +$3.07M
INSM icon
14
Insmed
INSM
$25.9B
$14.4M 2.32%
530,794
+2,644
+0.5% +$74K
ALXO icon
15
ALX Oncology
ALXO
$277M
$14.1M 2.27%
1,268,471
+3,712
+0.3% +$52.1K
VKTX icon
16
Viking Therapeutics
VKTX
$3.75B
$12.3M 1.98%
150,000
-175,284
-54% -$7.8M
NTLA icon
17
Intellia Therapeutics
NTLA
$1.8B
$11.9M 1.91%
432,598
+50,000
+13% +$1.39M
RGNX icon
18
Regenxbio
RGNX
$638M
$11.6M 1.86%
549,078
– –
RARE icon
19
Ultragenyx Pharmaceutical
RARE
$2.52B
$11.5M 1.84%
+245,590
New +$11.6M
MORF
20
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$11.5M 1.84%
325,333
+1,591
+0.5% +$53.3K
ETNB
21
DELISTED
89bio
ETNB
$11.3M 1.81%
+967,742
New +$10.7M
VRDN icon
22
Viridian Therapeutics
VRDN
$2.61B
$10.8M 1.73%
614,010
+514,010
+514% +$9.96M
FULC icon
23
Fulcrum Therapeutics
FULC
$294M
$10.7M 1.73%
+1,137,108
New +$10.2M
XERS icon
24
Xeris Biopharma Holdings
XERS
$1.55B
$9.21M 1.48%
4,166,496
+319,264
+8% +$826K
AXSM icon
25
Axsome Therapeutics
AXSM
$10.4B
$9.11M 1.46%
114,127
+20,740
+22% +$1.74M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q1 2024 Portfolio in Review

As of Q1 2024, MPM BioImpact held 44 positions worth $622M, up 46% from $427M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

MPM BioImpact deployed $80.5M of net new capital in Q1 2024, opening 12 new positions and adding to 14 existing holdings. Its largest new stake was Zentalis Pharmaceuticals: 1,516,183 shares worth $23.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $12.7M trimmed.

  • MPM BioImpact's largest Q1 2024 buy was Zentalis Pharmaceuticals: 1,516,183 shares worth $23.9M.
  • MPM BioImpact added most to Viridian Therapeutics in Q1 2024, an estimated $9.96M increase.
  • MPM BioImpact's biggest Q1 2024 reduction was Iovance Biotherapeutics, cutting an estimated $12.7M.
  • MPM BioImpact fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $16.9M.
  • MPM BioImpact's ten largest holdings make up 55% of its $622M portfolio in Q1 2024.
  • MPM BioImpact opened 12 new positions and closed 6 in Q1 2024.
  • MPM BioImpact's portfolio value rose 46% quarter-over-quarter to $622M.

Based on MPM BioImpact's 13F filing for Q1 2024, filed 15 May 2024.